Five Prime Therapeutics Reports Third Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Five Prime Therapeutics (FPRX) Misses Q3 EPS by 14c
November 3, 2020 4:10 PM ESTFive Prime Therapeutics (NASDAQ: FPRX) reported Q3 EPS of ($0.74), $0.14 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $2.05 million versus the consensus estimate of $3.41 million.
For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.
... More